A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- SCLC
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05026593
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Study of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05005455
- Locations
- 🇨🇳
The first affiliated hospital of Soochow university, Suzhou, Jiangsu, China
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 264
- Registration Number
- NCT05005234
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: IBI112 dose 4Drug: IBI112 dose 3Drug: IBI112 dose 1Drug: IBI112 dose 2Drug: placebo
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT05003531
- Locations
- 🇨🇳
PeKing University People's Hostpital, Beijing, Beijing, China
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 252
- Registration Number
- NCT04965506
- Locations
- 🇨🇳
China Japan Friendship Hospital, Beijing, Beijing, China
IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04945421
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of IBI323 in Patients With Advanced Malignancies
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 322
- Registration Number
- NCT04916119
- Locations
- 🇨🇳
Shang Hai Pulmonary Hospital, Shanghai, Shanghai, China
A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04911894
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04911881
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT04912466
- Locations
- 🇨🇳
Shandong Province Cancer Hospital, Jinan, Shandong, China
© Copyright 2025. All Rights Reserved by MedPath